A ‘designer’ manganese-peptide antioxidant of the world’s toughest bacterium, combined with radiation, have shown to be successful in the development of a vaccine to counter Venezuelan Equine Encephalitis Virus (VEEV), a biothreat agent, and Chikungunya virus, a mosquito-borne illness causing severe outbreaks around the world, according to a study “Deinococcus Mn2+-Peptide Complex: A Novel Approach to Alphavirus Vaccine Development,” published online May 30 in the journal, Vaccine, published by Elsevier, http://www.sciencedirect.com/
Effective vaccines depend upon the human immune system recognizing a biological structure that is similar to that of a disease-causing organism. A manganese-peptide antioxidant complex of Deinococcus, developed by Uniformed Services University of the Health Sciences (USU) pathology professor Dr. Michael J. Daly and his team, has the remarkable property of protecting proteins from ionizing radiation damage but not protecting the genetic material (DNA or RNA) in viruses and bacteria. Using D. radiodurans, listed in the Guinness Book of World Records as “the world’s toughest bacterium” and which can withstand 3,000 times the levels of gamma radiation that human cells can, Daly found that a disease-causing organism (pathogen) can be exposed to gamma radiation in the presence of a Deinococcus Mn complex, and rendered non-replicative (killed) by overwhelming genetic damage, but still maintain the shape of key surface proteins needed to mount a highly protective immune response. This approach was successfully implemented on viruses for the first time by scientists in the USU lab of the late Dr. Radha K. Maheshwari to produce vaccines against VEEV and Chikungunya virus.
This approach offers a simple, rapid, cost effective and potentially universal inactivation strategy that can be applied to any pathogen requiring immediate attention, for example, Ebola and Zika viruses.
“Application of this methodology has the potential to revolutionize all future vaccine development” says Dr. Paridhi Gupta, a scientist in the Maheshwari laboratory, and the study’s co-lead author.
The Latest on: Vaccine development
- GeoVax Comments on Recent Vaccine Development Study Funded by the Gates Foundation on September 19, 2018 at 7:59 am
ATLANTA, GA, Sept. 19, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (GOVX), a biotechnology company developing human vaccines, today commented on a research article describing a ... […]
- Researchers harness Zika virus vaccine under development to target glioblastoma on September 18, 2018 at 11:16 pm
Researchers at The University of Texas Medical Branch at Galveston have successfully harnessed a Zika virus vaccine under development to target and kill the brain cancer known as glioblastoma. The fin... […]
- All Vaccine Market 2018 -Positive Outlook, Demand, Revenue Generation, Market Shares, Latest Development & Leading Manufacturers on September 18, 2018 at 9:58 pm
Latest Research Study Titled, “All Vaccine Market By Type (Conjugate, Inactivated, Live Attenuated, Toxoid and Other Vaccine Types), Valance (Multivalent and Monovalent), Route of Administration (Inje... […]
- Philanthropy Bets Big on Sustainable Development Goals on September 18, 2018 at 10:04 am
This is a role that other funders, such as governments or international development agencies ... of the 22 funders made big bets to support innovative solutions, such as new vaccines; nearly all made ... […]
- Immune response mechanism described for fate determination of T cells on September 13, 2018 at 12:19 pm
University of Alabama at Birmingham. (2018, September 13). Immune response mechanism described for fate determination of T cells: This knowledge can aid vaccine development, treatment of infections an... […]
via Google News and Bing News